Summary
Significant Increase in AAV9 Production:
Promoter A demonstrated a 4.5-fold increase in AAV9 production compared to the standard
TESSA-RepCap9.
Achieved a peak titer of 3.1E+12 GC/mL, with a 10-fold improvement in overall productivity over
the traditional triple-transfection method.
Advantages of TESSA® Technology:
TESSA® outperformed the conventional triple-transfection method, offering greater scalability and
efficiency.
Optimized TESSA® constructs provide a robust platform for large-scale gene therapy
manufacturing.
TESSA® technology is integrated with our in-house testing capabilities, including biosafety
assessments, viral clearance, to facilitate AAV product approval.